Loading...
Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
There is no standard therapy for refractory acute myeloid leukemia (AML), but several salvage therapies are available (National Comprehensive Cancer Network [NCCN], 2018). Recently, there have been major developments in the treatment of AML focusing on the development of targeted and novel therapies...
Na minha lista:
| Udgivet i: | J Adv Pract Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Harborside Press LLC
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7779565/ https://ncbi.nlm.nih.gov/pubmed/33457062 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.5.7 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|